Drug Profile

Galvokimig - UCB Biopharma

Alternative Names: Galvokimig-UCB Biopharma; UCB-9741

Latest Information Update: 13 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator UCB Biopharma
Class Anti-inflammatories; Antibodies; Bispecific antibodies; Skin disorder therapies
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Atopic dermatitis

Most Recent Events

29 Dec 2025 Phase-II clinical trials in Atopic dermatitis in USA (Parenteral) (NCT07277660)
18 Sep 2025 UCB Biopharma plans a phase II trial for Atopic dermatitis (Injection) in December 2025 (NCT07277660) (EUCT2025-522578-35)
18 Sep 2025 Efficacy and adverse event data from phase I/IIa trial in Atopic dermatitis released by UCB Biopharma

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com